Thus, one would assume that while HER-3 positive tumor is killed by HER-3 reactive T cells, HER-3 negative tumor that activates other signaling pathways such as c-Met, EGFR, or HER-2 can still survive and become a major population. The gene discussed is ERBB3; the disease is neoplasm.